Researchers in a Shandong hospital compared a genetic test called metagenomic next-generation sequencing (mNGS) with conventional microbiological testing on bronchoalveolar lavage fluid from 136 patients with suspected pulmonary infections. The goal was to see which method more often identified germs and how results affected treatment decisions.
Overall, mNGS identified pathogens in 77.2% of patients, compared with 50.0% by conventional methods. It also showed higher sensitivity (74.6% vs. 46.7%) and detected mixed infections more often (19.1% vs. 8.8%). Mixed infections were more common in immunocompromised patients (35.1% vs. 13.1% in immunocompetent), and mNGS results led to more frequent adjustments to antimicrobial therapy in immunocompromised patients (56.8% vs. 35.4%).
Safety events were not reported. The study has important limits: it was retrospective, done at a single center, and it’s unclear if patients were selected consecutively or randomly. Because it compares diagnostic methods, it cannot show that treatment changes improve outcomes.
What to take away: mNGS can complement standard tests by finding more pathogens and mixed infections, especially in immunocompromised patients, but its impact on patient outcomes needs further study.
